	US 12,285,485 B2
	Methods of treating pain
Mahendra G. Shah, Mountain View, CA (US)
Assigned to Semnur Pharmaceuticals, Inc., Palo Alto, CA (US)
Filed by Semnur Pharmaceuticals, Inc., Palo Alto, CA (US)
Filed on Apr. 29, 2021, as Appl. No. 17/244,348.
Application 17/244,348 is a continuation of application No. 16/667,297, filed on Oct. 29, 2019, granted, now 11,020,485, issued on Jun. 1, 2021.
Application 16/667,297 is a continuation of application No. 15/545,204, granted, now 10,500,284, issued on Dec. 10, 2019, previously published as PCT/US2016/014165, filed on Jan. 20, 2016.
Claims priority of provisional application 62/106,045, filed on Jan. 21, 2015.
Prior Publication US 2021/0386859 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/36 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/573 (2006.01); A61K 31/661 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01)

CPC A61K 47/36 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 9/08 (2013.01); A61K 31/573 (2013.01); A61K 31/661 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01)]

29 Claims

1. A method for treating pain in an individual in need thereof, comprising:

injecting an aqueous pharmaceutical composition into an intralesional or intra-articular space of the individual, wherein the aqueous pharmaceutical composition comprises:

a soluble corticosteroid selected from the group consisting of soluble salts of dexamethasone, and at least one viscosity enhancing agent,

wherein the at least one viscosity enhancing agent is sodium hyaluronate or hyaluronic acid, the molecular weight of the at least one viscosity enhancing agent is between 500 kDa and

3.0 MDa, and the concentration of the at least one viscosity enhancing agent is between 1.0% w/v and 1.5% w/v;

and wherein the aqueous pharmaceutical composition does not comprise insoluble corticosteroids.